BONESUPPORT will commence direct sales in the Netherlands beginning in July 2020.
The company now has its own sales in Denmark, the Netherlands, Switzerland, the U.K., Sweden and Germany. In other European markets and in other parts of the world, the company cooperates with specialist distributors. BONESUPPORT’s previous Netherlands distributor will sell in parallel with BONESUPPORT in the region through the end of the year.
The company’s bone graft substitutes are based on the patented CERAMENT® technology platform. Ongoing clinical studies seek to further demonstrate the clinical and health economic benefits of CERAMENT products, and a Premarket Approval filing with FDA for antibiotic-releasing CERAMENT G is planned for 2021.
“We have a proven and scalable business model that has proved itself in a number of selected markets. We are now looking forward to adding the important Dutch market to our selected direct markets,” said Emil Billbäck, CEO of BONESUPPORT.
BONESUPPORT will commence direct sales in the Netherlands beginning in July 2020.
The company now has its own sales in Denmark, the Netherlands, Switzerland, the U.K., Sweden and Germany. In other European markets and in other parts of the world, the company cooperates with specialist distributors. BONESUPPORT's previous Netherlands...
BONESUPPORT will commence direct sales in the Netherlands beginning in July 2020.
The company now has its own sales in Denmark, the Netherlands, Switzerland, the U.K., Sweden and Germany. In other European markets and in other parts of the world, the company cooperates with specialist distributors. BONESUPPORT’s previous Netherlands distributor will sell in parallel with BONESUPPORT in the region through the end of the year.
The company’s bone graft substitutes are based on the patented CERAMENT® technology platform. Ongoing clinical studies seek to further demonstrate the clinical and health economic benefits of CERAMENT products, and a Premarket Approval filing with FDA for antibiotic-releasing CERAMENT G is planned for 2021.
“We have a proven and scalable business model that has proved itself in a number of selected markets. We are now looking forward to adding the important Dutch market to our selected direct markets,” said Emil Billbäck, CEO of BONESUPPORT.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
